Abstract
Bisphosphonates are synthetic derivatives of phosphonate, a normal constituent of bone. These agents are potent inhibitors of osteoclastic resorption, and as such are being explored for the management of various pathological conditions including osteoporosis, hypercalcemia, bone metastases and certain aspects of cancer. Among the first agents to be developed in the class, clodronic acid has shown conflicting results with respect to its ability to reduce osseous metastases, while pamidronic acid reduced hypercalcemia effectively compared with placebo in patients with breast cancer and multiple myeloma. Recent exploratory studies have shown that the novel bisphosphonate zoledronic acid reduces hypercalcemia more effectively than pamidronic acid in patients with various malignancies. In a recent phase III trial designed to show equivalence, zoledronic acid was as effective as pamidronic acid in the number of skeletal-related events arising over a predefined period of time. Furthermore, a trend in radiation therapy delay was observed in the zoledronic acid group. Zoledronic acid appears to be an effective agent in reducing the complications from bone involvement in cancer patients and it has shown efficacy in the prevention of osteoporosis in healthy postmenopausal women. For these reasons, it is being investigated as an adjunct to adjuvant therapy for postmenopausal patients with early breast cancer treated with nonsteroidal aromatase inhibitors, because efficient and prolonged estrogen deprivation with the latter agents may result in an increased risk of bone degradation in some patients.
Similar content being viewed by others
References
Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br J Cancer 1987; 55: 61–6
Coleman RE. Pathophysiology of metastatic bone disease: a rationale for treatment with osteoclast inhibitors [abstract]. Clin Exp Metastasis 1992; 10: 68
Powles TJ, McCloskey E, Paterson AH, et al. Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer. J Natl Cancer Inst 1998; 90: 704–8
Diel IJ, Solomayer EF, Costa SD, et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998; 339: 357–63
Saarto T, Vehmanen L, Elomaa I, et al. The effect of clodronate and antioestrogens on bone loss associated with oestrogen withdrawal in postmenopausal women with breast cancer. Br J Cancer 2001; 84: 1047–51
Hortobagyi GN, Theriault RL, Porter L, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 1996; 335: 1785–91
Hortobagyi GN, Theriault RL, Lipton A, et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol 1998; 16: 2038–44
Rogers MJ, Gordon S, Benford HL, et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000; 88: 2961–78
Green JR, Muller K, Jaeggi KA. Preclinical pharmacology of CGP 42,446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res 1994; 9: 745–51
Evans CE, Braidman IP. Effects of two novel bisphosphonates on bone cells in vitro. Bone Miner 1994; 26: 95–107
Boissier S, Ferreras M, Peyruchaud O, et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 2000; 60: 2949–54
Major P, Lortholary A, Hon J, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: apooledanalysis of two randomized controlled clinical trials. J Clin Oncol 2001; 19: 558–67
Berenson JR, Vescio RA, Rosen LS, et al. A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases. Clin Cancer Res 2001; 7: 478–85
Berenson JR, Vescio R, Henick K, et al. A Phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease. Cancer 2001; 91(1): 144–54
Berenson JR, Rosen LS, Howell A, et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 2001; 91: 1191–200
Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001; 7: 377–87
Senaratne SG, Pirianov G, Mansi JL, et al. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 2000; 82: 1459–68
The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial. Lancet 2002; 359: 2131–9
Acknowledgements
The author has provided no information on sources of funding or on conflicts of interest directly relevant to the content of this review.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Harvey, H.A. Therapeutic Use of Bisphosphonates in Breast Cancer. Am J Cancer 2 (Suppl 1), 19–25 (2003). https://doi.org/10.2165/00024669-200302001-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00024669-200302001-00004